Close
RNS Number : 6878V
ReNeuron Group plc
06 April 2023
 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Share Purchase by Senior Independent Non-Executive Director

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that Barbara Staehelin, Senior Independent Non-Executive Director of the Company, has today purchased 50,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

 

Name

Title

Number of Ordinary Shares purchased

Resulting beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Barbara Staehelin

Senior Independent NED

50,000

350,000

0.61%

 

                                                                                                                ENDS

 

 

 

Enquiries:

 

ReNeuron

www.reneuron.com/investors

Iain Ross, Executive Chairman

Via Walbrook PR

John Hawkins, Chief Financial Officer




Allenby Capital Limited (Nominated Adviser and Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

 

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com



Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Barbara Staehelin

2

Reason for the notification 

a)

Position/status 

Senior Independent Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

8.70p

50,000

d)

 

Aggregated information 

50,000 ordinary shares at an average price of 8.70p at a total value of £4350.00

e)

Date of the transaction 

06 April 2023

f)

Place of the transaction 

London Stock Exchange AIM Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUCGCUPWGAQ